Microba Life Sciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St · 08/30 20:19

Microba Life Sciences (ASX:MAP) Full Year 2024 Results

Key Financial Results

  • Revenue: AU$12.1m (up 123% from FY 2023).
  • Net loss: AU$19.9m (loss widened by 57% from FY 2023).
  • AU$0.049 loss per share (further deteriorated from AU$0.04 loss in FY 2023).
earnings-and-revenue-growth
ASX:MAP Earnings and Revenue Growth August 30th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Microba Life Sciences Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 13%.

Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Healthcare industry in Australia.

Performance of the Australian Healthcare industry.

The company's shares are down 5.3% from a week ago.

Risk Analysis

It is worth noting though that we have found 4 warning signs for Microba Life Sciences (1 doesn't sit too well with us!) that you need to take into consideration.